



MISSISSIPPI STATE DEPARTMENT OF HEALTH

**This is an official  
MS Health Alert Network (HAN) Alert**

**MESSAGE ID:** MSHAN-20220303-00562-ALT (Health Alert)  
**RECIPIENTS:** All Physicians, Hospitals, ERs, ICPs, NPs, PAs, and  
Healthcare Providers – Statewide  
Thursday, March 3, 2022  
**SUBJECT:** UPDATE: Bebtelovimab Monoclonal Antibody for the  
Treatment of Mild to Moderate COVID-19 Infection

### UPDATES

- On Friday, February 11, 2022, the FDA announced Emergency Use Authorization (EUA) for Eli Lilly's bebtelovimab, a monoclonal antibody product now authorized for the treatment of mild to moderate COVID-19 in adults and certain pediatric patients who are at high risk for progression to severe COVID-19.
- The EUA for sotrovimab has also recently been updated to reduce the treatment window to administration of therapy within 7 days of symptom onset.
- Please see the following resources for utilization of bebtelovimab and other therapeutics for COVID-19 treatment:
  - NIH COVID-19 Treatment Guidelines: [Therapies | COVID-19 Treatment Guidelines \(nih.gov\)](#)
  - Role of bebtelovimab for the treatment of high-risk, non-hospitalized patients with mild to moderate COVID-19: [Statement on Bebtelovimab | COVID-19 Treatment Guidelines \(nih.gov\)](#)
  - [Therapeutics Decision Aid \(phe.gov\)](#)

Bebtelovimab and sotrovimab are monoclonal antibody (mAb) medications authorized by the Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for the treatment of COVID-19. The mAbs are prescribed by authorized healthcare providers based on patient risk assessment. The United States Government has purchased these medications and allocates them on a weekly basis to states and jurisdictions.

To request supply of bebtelovimab and/or sotrovimab, please submit the MSDH Weekly Monoclonal Antibody Data Request survey on Tuesdays by 2:00 PM. If you need access to this survey, email [C19Therapeutics@msdh.ms.gov](mailto:C19Therapeutics@msdh.ms.gov).

Healthcare Provider fact sheets:

- [Sotrovimab Fact Sheet for HCP \(fda.gov\)](#)
- [Bebtelovimab Fact Sheet for HCP \(fda.gov\)](#)

570 East Woodrow Wilson • Post Office Box 1700 • Jackson, MS 39215-1700  
601-576-8090 • 1-866-HLTHY4U • [www.HealthyMS.com](http://www.HealthyMS.com)

*Equal Opportunity in Employment/Services*



MISSISSIPPI STATE DEPARTMENT OF HEALTH

Patients receiving monoclonal antibody therapy must be given a copy of the “Fact Sheet for Patients, Parents, and Caregivers” for the product they are receiving:

- [GSK Sotrovimab Fact Sheet for Patients, Parents, and Caregivers 02232022 \(fda.gov\)](#)
- [Fact Sheet for Patients, Parents and Caregivers Emergency Use Authorization \(EUA\) of Bebtelovimab for Coronavirus Disease 2019 \(COVID-19\) \(fda.gov\)](#)

Please email [C19Therapeutics@msdh.ms.gov](mailto:C19Therapeutics@msdh.ms.gov) with any questions or concerns.



***Alerting Message Specification Settings***

**Originating Agency:** Mississippi State Department of Health  
**Alerting Program:** MS Health Alert Network (MS HAN)  
**Message Identifier:** MSHAN-20220303-00562-ALT  
**Program (HAN) Type:** Health Alert  
**Status (Type):** Actual ()  
**Message Type:** Alert  
**Reference:** MSHAN-00562  
**Severity:** Unknown  
**Acknowledgement:** No  
**Sensitive:** Not Sensitive  
**Message Expiration:** Undetermined  
**Urgency:** Undetermined  
**Delivery Time:** 600 minutes

**Definition of Alerting Vocabulary and Message Specification Settings**

**Originating Agency:** A unique identifier for the agency originating the alert.

**Alerting Program:** The program sending the alert or engaging in alerts and communications using PHIN Communication and Alerting (PCA) as a vehicle for their delivery.

**Message Identifier:** A unique alert identifier that is generated upon alert activation (MSHAN-yyymmdd-hhmm-TTT (**ALT=Health Alert**, **ADV=Health Advisory**, **UPD=Health Update**, **MSG/INFO=Message/Info Service**)).

**Program (HAN) Type:** Categories of Health Alert Messages.

**Health Alert:** Conveys the highest level of importance; warrants immediate action or attention.

**Health Advisory:** Provides important information for a specific incident or situation; may not require immediate action.

**Health Update:** Provides updated information regarding an incident or situation; unlikely to require immediate action.

**Health Info Service:** Provides Message / Notification of general public health information; unlikely to require immediate action.

**Status (Type):**

Actual: Communication or alert refers to a live event  
Exercise: Designated recipients must respond to the communication or alert  
Test: Communication or alert is related to a technical, system test and should be disregarded

**Message Type:**

Alert: Indicates an original Alert



MISSISSIPPI STATE DEPARTMENT OF HEALTH

**Update:** Indicates prior alert has been Updated and/or superseded  
**Cancel:** Indicates prior alert has been cancelled  
**Error:** Indicates prior alert has been retracted

**Reference:** For a communication or alert with a Message Type of “Update” or “Cancel”, this attribute contains the unique Message Identifier of the original communication or alert being updated or cancelled. “n/a” = Not Applicable.

**Severity:**

**Extreme:** Extraordinary threat to life or property  
**Severe:** Significant threat to life or property  
**Moderate:** Possible threat to life or property  
**Minor:** Minimal threat to life or property  
**Unknown:** Unknown threat to life or property

**Acknowledgement:** Indicates whether an acknowledgement on the part of the recipient is required to confirm that the alert was received, and the timeframe in which a response is required (Yes or No).

**Sensitive:**

**Sensitive:** Indicates the alert contains sensitive content  
**Not Sensitive:** Indicates non-sensitive content

**Message Expiration:** Undetermined.

**Urgency:** Undetermined. Responsive action should be taken immediately.

**Delivery Time:** Indicates the timeframe for delivery of the alert (15, 60, 1440, 4320 minutes (.25, 1, 24, 72 hours)).